Good evening :)
$
₹
Lucid Diagnostics Inc

Lucid Diagnostics Inc

LUCD

NASDAQ
Asset Logo

Lucid Diagnostics Inc

LUCD

NASDAQ
$0.791.23% (+0.00)
$
₹
$0.791.23% (+0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Medical Devices

Micro Cap

With a market cap of $159.7M the stock is ranked 4406

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

13.83
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.41
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 6 analysts' reports

Buy
6 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +409.10% price upside over the next year

Current Price$0.79
Target Price$4

Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Peers

Peers

Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
33.01
33.01
1Y Return
23.69%
23.69%
Buy Reco %
74.07
74.07
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
37.34
37.34
1Y Return
9.01%
9.01%
Buy Reco %
88.00
88.00
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
43.29
43.29
1Y Return
11.99%
11.99%
Buy Reco %
66.66
66.66
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.09
23.09
1Y Return
2.88%
2.88%
Buy Reco %
53.12
53.12
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
29.14
29.14
1Y Return
27.02%
27.02%
Buy Reco %
68.75
68.75

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Lucid Diagnostics Inc -13.83-
Abbott Laboratories33.013.451.87
Danaher Corporation37.342.791.25

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

1.2
-10.3
1.5
-16.2
1.2
-13.9
1.4
-11.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue10.971.171.190.821.161.211.501.251.47
Net Income-10.61-11-12.37-11.54-26.90-4.43-10.39-16.26-13.90-11.68
Net Profit Margin-1060.13%-1127.56%-1055.54%-964.16%-3249.75%-381.68%-858.54%-1081.51%-1107.40%-792.87%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Lucid Diagnostics Inc (LUCD) share price today is $0.79 as of September 19, 2026 at 1:30 AM IST. The stock touched a day high of $0.79 and a day low of $0.76.

  2. Lucid Diagnostics Inc stock trades on NASDAQ under the ticker symbol LUCD.

  3. Lucid Diagnostics Inc's market capitalization is $159.7M as of September 19, 2026 at 1:30 AM IST.

  4. Lucid Diagnostics Inc's price-to-earnings (P/E) ratio is N/A as of September 18, 2026.

  5. Lucid Diagnostics Inc's price-to-book (P/B) ratio is 13.83 as of September 18, 2026.

  6. Yes, You can buy Lucid Diagnostics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Lucid Diagnostics Inc shares in three steps: 1. Search Lucid Diagnostics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Lucid Diagnostics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Lucid Diagnostics Inc (LUCD) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 12.6582 shares at the current price of $0.79.

Loading...